AR083578A1 - INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA - Google Patents
INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASAInfo
- Publication number
- AR083578A1 AR083578A1 ARP110103976A ARP110103976A AR083578A1 AR 083578 A1 AR083578 A1 AR 083578A1 AR P110103976 A ARP110103976 A AR P110103976A AR P110103976 A ARP110103976 A AR P110103976A AR 083578 A1 AR083578 A1 AR 083578A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- coa carboxylase
- lactama
- acetil
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 abstract 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 abstract 1
- 108010018763 Biotin carboxylase Proteins 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40812710P | 2010-10-29 | 2010-10-29 | |
| US201161531744P | 2011-09-07 | 2011-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083578A1 true AR083578A1 (es) | 2013-03-06 |
Family
ID=44993633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103976A AR083578A1 (es) | 2010-10-29 | 2011-10-27 | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8859773B2 (enExample) |
| EP (2) | EP2632925B1 (enExample) |
| JP (2) | JP5647356B2 (enExample) |
| KR (2) | KR20150006899A (enExample) |
| CN (2) | CN103189377B (enExample) |
| AR (1) | AR083578A1 (enExample) |
| AU (1) | AU2011322117B2 (enExample) |
| BR (1) | BR112013010310A2 (enExample) |
| CA (1) | CA2815169C (enExample) |
| CY (1) | CY1116405T1 (enExample) |
| DK (1) | DK2632925T3 (enExample) |
| ES (1) | ES2546465T3 (enExample) |
| HK (1) | HK1209733A1 (enExample) |
| HU (1) | HUE025078T2 (enExample) |
| IL (1) | IL225779A0 (enExample) |
| MX (1) | MX2013004733A (enExample) |
| NZ (1) | NZ609527A (enExample) |
| PL (1) | PL2632925T3 (enExample) |
| PT (1) | PT2632925E (enExample) |
| RU (1) | RU2540337C2 (enExample) |
| SG (1) | SG189883A1 (enExample) |
| SI (1) | SI2632925T1 (enExample) |
| TW (3) | TWI441823B (enExample) |
| UY (1) | UY33694A (enExample) |
| WO (1) | WO2012056372A1 (enExample) |
| ZA (1) | ZA201303882B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2632925T3 (pl) * | 2010-10-29 | 2015-10-30 | Pfizer | N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA |
| PT2953942T (pt) | 2013-02-06 | 2018-01-17 | Bayer Cropscience Ag | Derivados de pirazol substituídos com halogéneo como agentes pesticidas |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN103214327A (zh) * | 2013-03-22 | 2013-07-24 | 郑州泰基鸿诺药物科技有限公司 | 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法 |
| CN104230922B (zh) | 2013-06-19 | 2016-12-28 | 中国科学院上海药物研究所 | 一类五元杂环并吡啶类化合物及其制备方法和用途 |
| BR112016004118A2 (pt) | 2013-09-12 | 2017-10-17 | Pfizer | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar |
| BR112016017527B1 (pt) | 2014-01-03 | 2021-01-05 | Bayer Animal Health Gmbh | compostos, usos de compostos, composições farmacêuticas, processo para produzir composições e método não terapêutico para controlar pragas |
| CN104844509A (zh) * | 2014-02-14 | 2015-08-19 | 河南工业大学 | 一种条件温和无金属参与的胺基喹啉衍生物的制备方法 |
| KR101731624B1 (ko) * | 2014-07-01 | 2017-05-04 | 광주과학기술원 | 세포 리프로그래밍 유도용 조성물 |
| CN106749002A (zh) * | 2015-02-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途 |
| WO2016142394A1 (de) | 2015-03-10 | 2016-09-15 | Bayer Animal Health Gmbh | Pyrazolyl-derivate als schädlingsbekämpfungsmittel |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| UA125592C2 (uk) | 2017-03-16 | 2022-04-27 | Джянгсу Хенгруй Медісін Ко., Лтд. | ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ |
| WO2018170200A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| MX387359B (es) | 2017-03-16 | 2025-03-18 | Bristol Myers Squibb Co | Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos. |
| JP7129420B6 (ja) | 2017-03-30 | 2024-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｐｋ１阻害剤としてのイソキノリン |
| HUE061885T2 (hu) | 2017-11-21 | 2023-08-28 | Pfizer | 4-(4-(4-(1-Izopropil-7-oxo-1,4,6,6,7-tetrahidrospiro[indazol-5,4'-piperidin] -1'-karbonil)-6-metoxipiridin-2-il)-benzoesav kristályos 2-amino-2-(hidroximetil)-propán-1,3-diol sója |
| TW202019905A (zh) | 2018-07-24 | 2020-06-01 | 瑞士商赫孚孟拉羅股份公司 | 異喹啉化合物及其用途 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| CN109824669A (zh) * | 2018-12-21 | 2019-05-31 | 西南大学 | 哌啶螺环酒石酸类化合物制备及应用 |
| WO2021231191A1 (en) * | 2020-05-12 | 2021-11-18 | Merck Sharp & Dohme Corp. | Factor xi activation inhibitors |
| CN115666558A (zh) * | 2020-05-21 | 2023-01-31 | 盐野义制药株式会社 | 脂肪性肝病的治疗用药物 |
| CN116670142A (zh) | 2021-02-01 | 2023-08-29 | 细胞基因公司 | Mk2抑制剂、其合成和其中间体 |
| WO2022272036A1 (en) * | 2021-06-25 | 2022-12-29 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
| CN120019059A (zh) * | 2022-07-29 | 2025-05-16 | 辉瑞公司 | 新型acc抑制剂 |
| WO2024213044A1 (en) * | 2023-04-14 | 2024-10-17 | Beijing Double-Crane Runchuang Technology Co., Ltd. | Azacyclo-carbonyl-fused ring derivatives and use thereof |
| WO2025036472A1 (en) * | 2023-08-16 | 2025-02-20 | Pharmaengine, Inc. | Spirocyclic mta-cooperative prmts inhibitor |
| WO2025190395A2 (en) * | 2024-03-14 | 2025-09-18 | Pharmaengine, Inc. | Mta-cooperative prmt5 inhibitor |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2002100A (en) | 1932-06-27 | 1935-05-21 | Smith Sheffield | Shock absorber |
| JPS4925673B1 (enExample) * | 1970-05-22 | 1974-07-02 | ||
| EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
| JP4104983B2 (ja) | 2001-02-28 | 2008-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体 |
| BR0212123A (pt) | 2001-08-24 | 2004-07-20 | Upjohn Co | 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças |
| MXPA04007083A (es) | 2002-02-20 | 2004-10-29 | Upjohn Co | Compuestos azabiciclicos para el tratamiento de enfermedades. |
| EP1478437B1 (en) | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Acc inhibitors |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| JPWO2004092179A1 (ja) | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| ES2327857T3 (es) | 2004-05-12 | 2009-11-04 | Pfizer Products Inc. | Derivados de prolina y su uso como inhibidores de la dipeptidil peptidasa iv. |
| US20050267221A1 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of curcumin and analogues thereof as inhibitors of ACC2 |
| BRPI0510273A (pt) | 2004-05-25 | 2007-10-30 | Pfizer Prod Inc | derivados de tetraazabenzo[e]azuleno e análogos destes |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| US7410976B2 (en) | 2005-07-19 | 2008-08-12 | Merck & Co., Inc. | Spirochromanone derivatives |
| EP1911753A1 (en) | 2005-07-29 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| EP1951251B1 (en) | 2005-11-18 | 2010-12-29 | Merck Sharp & Dohme Corp. | Spirohydantoin aryl cgrp receptor antagonists |
| CN101384568B (zh) | 2006-02-15 | 2012-12-12 | 雅培制药有限公司 | 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| NL2000581C2 (nl) | 2006-04-20 | 2008-01-03 | Pfizer Prod Inc | Aangecondenseerde fenylamidoheterocyclische verbindingen. |
| EP2097420B1 (en) | 2006-11-29 | 2012-04-04 | Pfizer Products Inc. | Spiroketone inhibitors of acetyl-coa carboxylase |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| WO2008102749A1 (ja) | 2007-02-20 | 2008-08-28 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
| JP5404601B2 (ja) | 2007-04-12 | 2014-02-05 | ファイザー・インク | 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体 |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| EP2297163B1 (en) | 2008-05-28 | 2015-07-08 | Pfizer Inc. | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
| WO2010002010A1 (en) | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co.,Ltd. | Novel spirochromanone carboxylic acids |
| US8110570B2 (en) | 2008-07-14 | 2012-02-07 | Cropsolution, Inc. | Modulators of acetyl-coenzyme A carboxylase and methods of use thereof |
| WO2010013161A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
| ATE540040T1 (de) | 2008-08-28 | 2012-01-15 | Pfizer | Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| UA99882C2 (uk) | 2009-03-11 | 2012-10-10 | Пфайзер Інк. | Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти) |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| WO2010128425A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| CA2778886C (en) | 2009-11-10 | 2014-01-07 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA2778316A1 (en) * | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| PT2621493T (pt) | 2010-09-30 | 2016-11-14 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| PL2632925T3 (pl) * | 2010-10-29 | 2015-10-30 | Pfizer | N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA |
-
2011
- 2011-10-18 PL PL11784783T patent/PL2632925T3/pl unknown
- 2011-10-18 SI SI201130519T patent/SI2632925T1/sl unknown
- 2011-10-18 SG SG2013027446A patent/SG189883A1/en unknown
- 2011-10-18 RU RU2013116924/04A patent/RU2540337C2/ru not_active IP Right Cessation
- 2011-10-18 EP EP11784783.0A patent/EP2632925B1/en not_active Not-in-force
- 2011-10-18 HU HUE11784783A patent/HUE025078T2/en unknown
- 2011-10-18 NZ NZ609527A patent/NZ609527A/en not_active IP Right Cessation
- 2011-10-18 JP JP2013535549A patent/JP5647356B2/ja not_active Expired - Fee Related
- 2011-10-18 DK DK11784783.0T patent/DK2632925T3/en active
- 2011-10-18 ES ES11784783.0T patent/ES2546465T3/es active Active
- 2011-10-18 MX MX2013004733A patent/MX2013004733A/es unknown
- 2011-10-18 CN CN201180052416.2A patent/CN103189377B/zh not_active Expired - Fee Related
- 2011-10-18 PT PT117847830T patent/PT2632925E/pt unknown
- 2011-10-18 BR BR112013010310A patent/BR112013010310A2/pt not_active IP Right Cessation
- 2011-10-18 CA CA2815169A patent/CA2815169C/en not_active Expired - Fee Related
- 2011-10-18 KR KR20147036653A patent/KR20150006899A/ko not_active Withdrawn
- 2011-10-18 KR KR1020137013652A patent/KR101529404B1/ko not_active Expired - Fee Related
- 2011-10-18 EP EP15164071.1A patent/EP2952514A1/en not_active Withdrawn
- 2011-10-18 CN CN201510087893.2A patent/CN104774205A/zh active Pending
- 2011-10-18 WO PCT/IB2011/054643 patent/WO2012056372A1/en not_active Ceased
- 2011-10-18 AU AU2011322117A patent/AU2011322117B2/en not_active Ceased
- 2011-10-26 TW TW100138909A patent/TWI441823B/zh not_active IP Right Cessation
- 2011-10-26 TW TW103102453A patent/TWI507406B/zh not_active IP Right Cessation
- 2011-10-26 TW TW104115757A patent/TW201531472A/zh unknown
- 2011-10-27 US US13/282,964 patent/US8859773B2/en active Active
- 2011-10-27 AR ARP110103976A patent/AR083578A1/es unknown
- 2011-10-28 UY UY0001033694A patent/UY33694A/es not_active Application Discontinuation
-
2013
- 2013-04-15 IL IL225779A patent/IL225779A0/en unknown
- 2013-05-28 ZA ZA2013/03882A patent/ZA201303882B/en unknown
-
2014
- 2014-09-26 US US14/497,396 patent/US8993586B2/en active Active
- 2014-11-05 JP JP2014225021A patent/JP2015057416A/ja not_active Withdrawn
-
2015
- 2015-02-13 US US14/621,723 patent/US9181252B2/en active Active
- 2015-06-12 CY CY20151100518T patent/CY1116405T1/el unknown
- 2015-10-22 HK HK15110405.1A patent/HK1209733A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
| AR078944A1 (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
| MY162167A (en) | Substituted acetyl-coa carboxylase inhibitors | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
| AR084433A1 (es) | Inhibidores de la faah y composiciones farmaceuticas que los contienen | |
| PE20141120A1 (es) | Compuestos heterociclicos | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| BR112015010102A2 (pt) | compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifnalfa | |
| EA201490493A1 (ru) | Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы | |
| EA201270646A1 (ru) | Ингибиторы глюкозилцерамидсинтазы | |
| MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| EA201070592A1 (ru) | Ингибиторы пептиддеформилазы | |
| BR112015009798A2 (pt) | compostos de pirimidina substituídos por alquil amida úteis na modulação de il-12, il-23 e/ou ifnalfa | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| CO6341610A2 (es) | Compuesto heterociclilo aromatico que contiene nitrogeno. | |
| EA201171011A1 (ru) | Производные 6-(6-o-замещенный триазолопиридазинсульфанил)бензотиазолов и -бензимидазолов: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов met | |
| CO6351744A2 (es) | Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridini-3-il]-2-metil-4´-(trifluoro-metoxi)-[1,1´-bifenil]-3-carboxamida | |
| UY33150A (es) | Compuestos carboxamida y su uso como inhibidores v de calpaína | |
| CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |